Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 791

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 791
---
) |   | $ | 37,500 |   |
| Issuance costs                                                        |   | ​ | -1,025 | ​ |
| Non-cash interest expense                                             |   | ​ |    604 | ​ |
| Balance at December 31, 2023                                          | ​ | $ | 37,079 | ​ |
| ​                                                                     | ​ | ​ |      ​ | ​ |
| Effective interest rate                                               | ​ |   |   22.6 | % |

11. Stockholders’ Equity The Company’s Board of Directors has authorized 8,333,333shares of the Company’s common stock, par value $ 0.001per share, and 5,000,000shares of undesignated preferred stock, par value $ 0.001per share, that may be issued from time to time by the Board of Directors of the Company in one or more series. As of December 31, 2023, there were 4,540,059shares of commonstock and noshares of preferred stock issued and outstanding. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to dividends when and if declared by the Board of Directors, subject to the preferential rights of the holders of preferred stock, if any. In October 2023, as a result of completion of the quarterly vesting period for restricted stock units granted in October 2021, an aggregate of 740 time-based restricted stock units vested and were settled in shares of the Company’s common stock (see Note 15, Stock-Based Compensation ). In August 2023, as a result of completion of the vesting period for restricted stock units granted in October 2022, an aggregate of 606 time-based restricted stock units vested and were settled in shares of the Company’s common stock (see Note 15, Stock-Based Compensation ). In July 2023, as a result of completion of the quarterly vesting period for restricted stock units granted in October 2021, an aggregate of 740 time-based restricted stock units vested and were settled in shares of the Company’s common stock (see Note 15, Stock-Based Compensation ). In June 2023, as a result of completion of the final vesting period for restricted stock units granted in December 2021, an aggregate of 2,183 time-based restricted stock units vested and were settled in shares of the Company’s common stock (